Maxim Kots

825 total citations
18 papers, 174 citations indexed

About

Maxim Kots is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Maxim Kots has authored 18 papers receiving a total of 174 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 12 papers in Physiology and 1 paper in Pediatrics, Perinatology and Child Health. Recurrent topics in Maxim Kots's work include Asthma and respiratory diseases (12 papers), Inhalation and Respiratory Drug Delivery (8 papers) and Respiratory and Cough-Related Research (6 papers). Maxim Kots is often cited by papers focused on Asthma and respiratory diseases (12 papers), Inhalation and Respiratory Drug Delivery (8 papers) and Respiratory and Cough-Related Research (6 papers). Maxim Kots collaborates with scholars based in Italy, United Kingdom and Germany. Maxim Kots's co-authors include George Georges, J. Christian Virchow, Dave Singh, Alberto Papi, Giorgio Walter Canonica, Stefano Petruzzelli, Pierluigi Paggiaro, Piotr Kuna, Pierluigi Paggiaro and Ian Pavord and has published in prestigious journals such as The Lancet, Journal of Allergy and Clinical Immunology and Value in Health.

In The Last Decade

Maxim Kots

16 papers receiving 174 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maxim Kots Italy	4	167	156	12	11	7	18	174
Rabih Klink United Kingdom	3	48 0.3×	47 0.3×	3 0.3×	3 0.3×	1 0.1×	4	60
Antonio Perrella Italy	4	64 0.4×	45 0.3×	17 1.4×	1 0.1×	12 1.7×	6	71
Breda Flood Greece	3	53 0.3×	22 0.1×	40 3.3×	3 0.3×	7 1.0×	3	68
Bipen D. Patel United Kingdom	3	49 0.3×	114 0.7×		19 1.7×	6 0.9×	5	127
Minyoung Cho United States	3	40 0.2×	40 0.3×		41 3.7×	2 0.3×	6	97
Neil Fitch Malaysia	2	28 0.2×	14 0.1×	13 1.1×	3 0.3×	17 2.4×	3	43
E Valovirta Denmark	6	127 0.8×	47 0.3×	117 9.8×	2 0.2×	1 0.1×	7	145
Heidi Schaarschmidt Germany	2	30 0.2×	29 0.2×		9 0.8×	6 0.9×	2	46
Bina Choi United States	5	19 0.1×	71 0.5×		4 0.4×	2 0.3×	15	84
Kamran Tariq United Kingdom	2	17 0.1×	15 0.1×	7 0.6×	3 0.3×	12 1.7×	7	34

Countries citing papers authored by Maxim Kots

Since Specialization

Citations

This map shows the geographic impact of Maxim Kots's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maxim Kots with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maxim Kots more than expected).

Fields of papers citing papers by Maxim Kots

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maxim Kots. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maxim Kots. The network helps show where Maxim Kots may publish in the future.

Co-authorship network of co-authors of Maxim Kots

This figure shows the co-authorship network connecting the top 25 collaborators of Maxim Kots. A scholar is included among the top collaborators of Maxim Kots based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maxim Kots. Maxim Kots is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Price, David, William Henley, José Eduardo Delfini Cançado, et al.. (2024). Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS. PubMed. Volume 15. 1–16. 2 indexed citations

Nikolaidis, Georgios, et al.. (2023). EE556 Beclometasone/Formoterol/Glycopyrronium Vs. Fixed and Open Combinations of Inhaled Corticosteroids, Long-Acting B2-Agonist, and Long-Acting Muscarinic Antagonist in Adults with Uncontrolled Asthma: A Network Meta-Analysis. Value in Health. 26(12). S159–S160.

Hartman, Jorine E., Monica Kraft, Salman Siddiqui, et al.. (2023). Cluster analysis to identify distinct clinical asthma phenotypes within ATLANTIS. OA1525–OA1525. 1 indexed citations

Richardson, Matthew, Janwillem Kocks, S. Baldi, et al.. (2023). Associations of imaging biomarkers with physiological markers of small airways dysfunction in asthma in the ATLANTIS study.. OA1529–OA1529. 1 indexed citations

Κostikas, Κonstantinos, et al.. (2023). The MiSTIC Study Design: Medium Strength Triple Therapy Vs High Strength ICS/LABA for Adult Patients With Asthma Uncontrolled on Medium Strength ICS/LABA. A1310–A1310. 1 indexed citations

Henley, William, Derek Skinner, Rebecca Vella, et al.. (2022). Predicting Pneumonia Events in COPD Patients Using Medical Records. A2400–A2400.

Papi, Alberto, J. Christian Virchow, Dave Singh, et al.. (2021). Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses. Journal of Allergy and Clinical Immunology. 148(1). 262–265.e2. 8 indexed citations

Kots, Maxim, et al.. (2021). CHF 6366: A Novel Dual Potent Bronchodilator with Antimuscarinic and Beta-2 Agonist Activity - Results from the First-in-Human Healthy Male Volunteers Trial. A2253–A2253. 1 indexed citations

Kots, Maxim, George Georges, Alessandro Guasconi, & C. Franz Vogelmeier. (2021). S26 Effect of single-inhaler extrafine beclometasone/formoterol/glycopyrronium pMDI (BDP/FF/GB) compared with two-inhaler fluticasone furoate/vilanterol DPI + tiotropium DPI (FLF/VIL+TIO) triple therapy on health-related quality of life (HRQoL) in patients with COPD: The TRISTAR study. A20.1–A20. 1 indexed citations

10.

Singh, Dave, J. Christian Virchow, Giorgio Walter Canonica, et al.. (2020). Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. Respiratory Research. 21(1). 285–285. 21 indexed citations

11.

Shrimanker, Rahul, Clare Connolly, Samantha Thulborn, et al.. (2019). Late Breaking Abstract - Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma. RCT3784–RCT3784. 2 indexed citations

12.

Virchow, J. Christian, Pierluigi Paggiaro, Giorgio Walter Canonica, et al.. (2019). Effect of extrafine medium strength (MS) ICS-containing triple therapy on exacerbations in asthmatics with persistent airflow limitation: A post-hoc analysis of the TRIMARAN study. PA3719–PA3719. 1 indexed citations

13.

Virchow, J. Christian, Piotr Kuna, Pierluigi Paggiaro, et al.. (2019). Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. The Lancet. 394(10210). 1737–1749. 127 indexed citations

14.

Canonica, Giorgio Walter, et al.. (2019). Efficacy and Safety of High ICS Dose Fixed-Combination ICS/LABA/LAMA pMDI Compared with ICS/LABA and ICS/LABA + LAMA in Patients with Uncontrolled Asthma: The TRIGGER Study. A7362–A7362. 1 indexed citations

15.

Virchow, J. Christian, et al.. (2019). Reducing the Rate of Severe Asthma Exacerbations Using Single-Inhaler Extrafine BDP/FF/GB Combination Compared to BDP/FF in Patients with Uncontrolled Asthma: Pooled Results from the TRIMARAN and TRIGGER Studies</bold>. A7363–A7363. 3 indexed citations

16.

Canonica, Giorgio Walter, J. Christian Virchow, David Singh, et al.. (2019). Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study. OA5339–OA5339. 1 indexed citations

17.

Singh, Dave, J. Christian Virchow, Giorgio Walter Canonica, et al.. (2019). Characteristics of prominent response to triple therapy in patients with asthma uncontrolled on ICS/LABA: A stratified analysis of the TRIMARAN and TRIGGER studies. RCT3779–RCT3779. 2 indexed citations

18.

Paggiaro, Pierluigi, et al.. (2019). Efficacy and Safety of a Fixed Combination Extrafine Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide (BDP/FF/GB) pMDI Treatment Compared to Fixed Combination BDP/FF in Patients with Uncontrolled Asthma on Medium Dose ICS/LABA: The TRIMARAN Study. A7080–A7080. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact